共 50 条
- [1] Cost-effectiveness analysis of HLA-B*58:01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population [J]. PHARMACOGENETICS AND GENOMICS, 2018, 28 (02): : 56 - 67
- [2] Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population [J]. PHARMACOGENETICS AND GENOMICS, 2009, 19 (09): : 704 - 709
- [4] Allopurinol-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis overlap syndrome [J]. GALICIA CLINICA, 2021, 82 (01): : 57 - 57
- [5] Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis [J]. BMC MEDICAL GENETICS, 2011, 12
- [8] Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS']JS/TEN in Thai Population [J]. PLOS ONE, 2014, 9 (04):
- [10] A response letter to allopurinol-induced toxic epidermal necrolysis and association with HLA-B*5801 in White patients [J]. PHARMACOGENETICS AND GENOMICS, 2018, 28 (12): : 268 - 269